Please assess the completion status of the following clinical trial:

Trial Title: CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged \>= 6 months to 12 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including but not limited to one or more of the following:~   * fever at the time of evaluation (axillary temperature 37.5° C by digital thermometer)~  * report of fever within the last two days~  * profound anemia (conjunctival or palmar pallor)~  * headache~  * body aches~  * abdominal pain~  * decreased intake of food or fluids~  * weakness~2. Positive malaria smear for P. falciparum mono-infection~3. Parasite density of 2,000-200,000/microliter or \< 10%~4. Willingness to remain at the Health Centre under continuous observation until the resolution of the infection~5. Parental consent for each participant, and child assent for children older than 5 years~Exclusion Criteria:~1. Signs of severe malaria: One or more of the following:~   * hemoglobin \< 5 g/dl~  * parasitemia \> 10%~  * prostration \* as indicated by inability to drink or breastfeed~  * respiratory distress (deep Kussmaul respirations)~  * bleeding~  * recent seizures\*, coma\* or mental obtundation\* (Blantyre coma score less than 5)~  * persistent vomiting\*~2. Presence of a severe disease~3. Presence of a febrile condition caused by diseases other than malaria~4. Known allergy or history of adverse reaction to sulfadoxine/pyrimethamine (SP), sulfa drugs or chloroquine~5. Chronic medication with an antifolate drug~6. Enrollment in this clinical study in the past 28 days \*Each of these symptoms or signs is considered a danger sign.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).